Skip to main content

HER2 testing for overexpression or gene amplification in patients with breast cancer

CBE ID
1878
1.4 Project
Cancer
Endorsed
Endorsement Status
Endorsement Removed
1.1 New or Maintenance
Maintenance
E&M Cycle
Fall 2020
Is Under Review
No
1.3 Measure Description

Proportion of female patients (aged 18 years and older) with breast cancer who receive human epidermal growth factor receptor 2 (HER2) testing for overexpression or gene amplification

    • 1.14 Numerator

      HER2 testing performed

    • 1.15 Denominator

      Adult women with breast cancer

    • Exclusions

      None

    • Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Cancer Fall Cycle 2020
      Initial Endorsement
      Last Updated
      Removal Date
    • Steward
      American Society of Clinical Oncology
      Steward Organization Email
      [email protected]
      Steward Organization Copyright

      The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.
      The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.
      Commercial uses of the Measures require a license agreement between the user and the American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (PCPI®)] or American Society of Clinical Oncology (ASCO). Neither the AMA, ASCO, PCPI, nor its members shall be responsible for any use of the Measures.
      The AMA’s and PCPI’s significant past efforts and contributions to the development and updating of the Measures is acknowledged. ASCO is solely responsible for the review and enhancement (“Maintenance”) of the Measures as of 2016.
      ASCO encourages use of the Measures by other health care professionals, where appropriate.
      THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

      © 2012-2016 American Medical Association and American Society of Clinical Oncology. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
      Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, ASCO, the PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.
      CPT® contained in the Measures specifications is copyright 2004-2013 American Medical Association. LOINC® copyright 2004-2013 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2013 College of American Pathologists. All Rights Reserved.